SLC5A3 and pancreatic adenocarcinoma: Survival analysis of multiple patient cohorts, including TCGA–PAAD and SNU cohorts, revealed that high SLC5A3 expression was associated with significantly poor overall survival, highlighting its potential as a prognostic marker for pancreatic cancer (Figs. 1E and S1B).